4-Antibody’s first R&D collaboration with a major pharma partner, Boehringer Ingelheim, commenced in early 2010 and is a long-term collaboration to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. The collaboration centres on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid antibody discovery and also incorporates the novel, rapid, in vivo Hu-PAC® technology for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.

Robert Burns, 4-Antibody’s CEO, said: “Long-term collaborations serve an important role in validating technology platforms and so we’re delighted to announce that we’ve successfully delivered on the first major milestone in this key multi-target collaboration.  I’d expect this to add further momentum to our other ongoing partnering activities.”